Apotheek Pape SRL
Apotheek Pape reported total assets of 581,717 € at the end of the 2025 financial year (annual accounts filed with the NBB on 30 Jun 2026).
The score of Apotheek Pape shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +6 % Total assets +10 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Apotheek Pape's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | 52,558 € | ||||
| Equity | 169,485 € | ||||
| Cash | 26,600 € | ||||
| EBITDA | 78,514 € | ||||
| Total assets | 581,717 € |
Filed annual accounts
- Year ended 31 Dec 2025filed on 30 Jun 2026
- Year ended 31 Dec 2024filed on 27 Jun 2025
- Year ended 31 Dec 2023filed on 30 Aug 2024
- Year ended 31 Dec 2022filed on 06 Jul 2023
- Year ended 31 Dec 2021filed on 28 Jun 2022
Apotheek Pape's financial analysis
- Solvency29.1%sector median: 44.2%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Apotheek Pape
Apotheek Pape's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0418.743.159
- VAT number
- BE0418743159
- Peppol
- Registered · 0208:0418743159 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 26 Sep 1978
- Registered office
- 8600 Diksmuide
- Latest accounts
- 2025 · filed on 30 Jun 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
Apotheek Pape (SRL) has been based in Diksmuide since 1978, active in: retail sale of pharmaceutical products. For 2025, it reports a net profit of 52,558 € and equity of 169,485 €; its revenue is not published. Its solvency stands at 29.1%, below the median of its sector (44.2%).
Companies similar to Apotheek Pape
Companies in the same business, of comparable size and area, outside its group.
- Belpharma Retail sale of pharmaceutical products Namur · balance sheet 581,313 €
- Medipharm Retail sale of pharmaceutical products Evere · balance sheet 583,033 €
- Eeuwfeestapotheek Retail sale of pharmaceutical products Antwerp · balance sheet 583,835 €
- Maertens Pharma Associes Retail sale of pharmaceutical products Chimay · balance sheet 583,944 €
- Beirnaert VG Retail sale of pharmaceutical products Destelbergen · balance sheet 584,335 €
- Pharmacie DE Jalhay Retail sale of pharmaceutical products Chaudfontaine · balance sheet 584,400 €
- Apoteek DE Coster Retail sale of pharmaceutical products Zaventem · balance sheet 578,522 €
- Pharmax Retail sale of pharmaceutical products Liège · balance sheet 586,278 €
Frequently asked questions about Apotheek Pape
What is the revenue of Apotheek Pape?
Apotheek Pape files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Apotheek Pape?
In Belgium, the VAT number is the company number prefixed with BE: BE0418743159 for Apotheek Pape, if the company is VAT-registered. Its company number (CBE) is 0418.743.159.
Where is the registered office of Apotheek Pape?
According to the CBE register, the registered office of Apotheek Pape is in 8600 Diksmuide.
What is the equity of Apotheek Pape?
At the close of the 2025 financial year, the equity of Apotheek Pape amounts to 169,485 €, a solvency of 29.1% of total assets.
Who manages Apotheek Pape?
The register lists 3 active mandates at Apotheek Pape. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Apotheek Pape
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →